

TaylorWessing

# AI in Life Sciences Academy

## Agenda

09:00	Registration
09:30	Welcome
09:40	What really is AI? (Alexandra Ebert, Chief Trust Officer at MOSTLY AI)
10:00	<b>AI and ethics – how could AI be unethical and what does this mean for businesses deploying AI or selling AI-enabled products?</b> <ul style="list-style-type: none"><li>▪ Bias</li><li>▪ Inequality of treatment/outcomes</li><li>▪ Ethics and trust</li><li>▪ What is the harm that could arise?</li></ul>
10:30	<b>The Artificial Intelligence Act – how might it apply to AI used in healthcare? How does this approach compare with the UK/US?</b> <ul style="list-style-type: none"><li>▪ Medical devices – an additional layer of regulation?</li><li>▪ Platforms for drug discovery, telehealth solutions – what are the guard rails for regulation?</li></ul>
11:00	<b>The future of AI regulation in the UK: the new medical device regulations and AIaMD as a subset of SaMD.</b>  Scene setting - what the MHRA has said so far: <ul style="list-style-type: none"><li>▪ Intended purpose (see MHRA guidance)</li><li>▪ Risk assessment</li></ul>
11:30	Refreshment break

11:45	<p><b>Use of AI to recruit, manage and train your personnel – what are the implications for your business?</b></p> <ul style="list-style-type: none"> <li>▪ Employment law</li> <li>▪ Data privacy</li> <li>▪ Liability and transparency</li> </ul>
12:15	<p><b>Deals in AI products:</b></p> <ul style="list-style-type: none"> <li>▪ Due diligence – what do you need to understand/ verify when buying a company developing/ selling AI product?</li> <li>▪ Licensing AI products: key points that differentiate AI licensing deals from others.</li> </ul>
12:45	Lunch
13:30	<p><b>What could AI mean for patent rights – applying case law to this newer technology – what are the implications?</b></p>
13:45	<p><b>Data privacy: applying the principles of GDPR to data used in the creation and operation of AI devices, platforms and products, including medical devices:</b></p> <ul style="list-style-type: none"> <li>▪ The additional challenges of AI under GDPR across the EU plus the implications of following ICO guidance on AI in the UK.</li> <li>▪ Generative AI and GDPR.</li> <li>▪ Is synthetic data the answer? A discussion with <b>Paula Garcia, Global DPO and privacy counsel at Illumina.</b></li> </ul>
15:00	Refreshment break
15:15	<p><b>A comparative approach to getting digital health products onto the market in the UK, France and Germany:</b></p> <ul style="list-style-type: none"> <li>▪ Who needs to be convinced?</li> <li>▪ Is there a pricing/reimbursement issue?</li> <li>▪ Advertising your AI device</li> <li>▪ Working with clinicians on AI product development</li> <li>▪ German special route for AI/digital health products (DiGA procedure)</li> </ul>
16:00	<p><b>How could AI lead to dominance and the implications of AI for competition in the marketplace?</b></p>
16:30	Drinks reception